Exelixis Inc Increase (Decrease) in Contract with Customer, Asset
Exelixis Inc (EXEL) reported Increase (Decrease) in Contract with Customer, Asset of $2.64 million for the 9-month period ending 2019-09-27, per its 10-Q filed 2019-10-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2019-10-30
- Exelixis Inc increase (decrease) in contract with customer, asset for the quarter ending 2019-09-27 was $490.00K, a 98.50% decline year-over-year.
- Exelixis Inc increase (decrease) in contract with customer, asset for the quarter ending 2019-06-28 was -$5.60M.
- Exelixis Inc increase (decrease) in contract with customer, asset for the quarter ending 2019-03-29 was $7.75M, a 79.60% decline year-over-year.
- Exelixis Inc increase (decrease) in contract with customer, asset for the quarter ending 2018-09-28 was $32.67M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month |
|---|---|---|---|
| 2019-09-27 | $490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$5.11M derived: sum of 2 quarters · filed 2019-10-30 | $2.64M 10-Q · filed 2019-10-30 |
| 2019-06-28 | -$5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $2.15M 10-Q · filed 2019-07-31 | |
| 2019-03-29 | $7.75M 10-Q · filed 2019-05-01 | ||
| 2018-09-28 | $32.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$5.34M derived: sum of 2 quarters · filed 2019-10-30 | $32.67M 10-Q · filed 2019-10-30 |
| 2018-06-29 | -$38.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $0.00 10-Q · filed 2019-07-31 | |
| 2018-03-30 | $38.01M 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |